tiprankstipranks
Trending News
More News >
Bayer Cropscience India Limited (IN:BAYERCROP)
:BAYERCROP
India Market
Advertisement

Bayer Cropscience India Limited (BAYERCROP) AI Stock Analysis

Compare
2 Followers

Top Page

IN:BAYERCROP

Bayer Cropscience India Limited

(BAYERCROP)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
₹4,747.00
▲(2.16% Upside)
Bayer Cropscience India Limited's overall stock score is primarily influenced by its strong financial performance, characterized by stable revenue growth and a robust balance sheet. However, bearish technical indicators and a relatively high P/E ratio suggest caution. The stock's valuation and technical analysis indicate potential risks, while the absence of earnings call data and corporate events limits additional insights.
Positive Factors
Strong Balance Sheet
A robust balance sheet with low leverage enhances financial stability and flexibility, allowing for strategic investments and resilience against economic fluctuations.
Revenue Growth
Sustained revenue growth indicates strong market demand and effective product positioning, supporting long-term business expansion and competitiveness.
Cash Reserves
Strong cash reserves provide a buffer against economic downturns and enable the company to seize growth opportunities without financial strain.
Negative Factors
Declining Profit Margins
Decreasing profit margins suggest rising costs or pricing pressures, which could impact profitability and require strategic adjustments to maintain competitiveness.
Operating Cash Flow Decrease
A decline in operating cash flow may limit the company's ability to fund operations and invest in growth, necessitating improved cash management strategies.
Net Profit Margin Decline
Falling net profit margins indicate reduced profitability, which could affect future earnings and shareholder returns if not addressed through cost control or revenue enhancement.

Bayer Cropscience India Limited (BAYERCROP) vs. iShares MSCI India ETF (INDA)

Bayer Cropscience India Limited Business Overview & Revenue Model

Company DescriptionBayer Cropscience India Limited (BAYERCROP) is a leading agricultural solutions company in India, dedicated to providing innovative products and services that enhance crop productivity and protect against pests and diseases. A subsidiary of Bayer AG, BAYERCROP operates in the crop protection, seeds, and biotechnology sectors, offering a diverse portfolio that includes herbicides, fungicides, insecticides, and high-quality seeds for various crops. The company focuses on sustainable agricultural practices, supporting farmers with cutting-edge technologies and solutions to meet the challenges of food security and environmental sustainability.
How the Company Makes MoneyBayer Cropscience India Limited generates revenue primarily through the sale of agricultural chemicals, including crop protection products such as herbicides and insecticides, as well as seeds and biotechnology products. The company's revenue model is based on a combination of direct sales to farmers and distribution through a network of retailers and agricultural cooperatives. Key revenue streams include product sales in both domestic and export markets, with significant contributions from premium products that offer advanced formulations and sustainable solutions. Additionally, BAYERCROP engages in partnerships with research institutions, agricultural organizations, and other stakeholders to enhance product development and market reach, further contributing to its earnings.

Bayer Cropscience India Limited Financial Statement Overview

Summary
Bayer Cropscience India Limited demonstrates a strong financial position with stable revenue growth and a solid balance sheet featuring low leverage and high equity. However, the decrease in profit margins and operating cash flow in 2025 presents a challenge. The company's strong cash reserves and capital structure mitigate risks, but addressing margin pressures is crucial for sustaining future growth.
Income Statement
75
Positive
Bayer Cropscience India Limited has shown consistent revenue growth, with Total Revenue increasing from 2020 to 2025. However, gross profit margin declined significantly from 45.36% in 2024 to 28.14% in 2025, indicating rising cost pressures or pricing issues. Net profit margin also decreased from 14.50% in 2024 to 10.38% in 2025. Despite these declines, the company maintains a solid EBIT margin in 2025 at 11.05% and an EBITDA margin of 14.79%, reflecting efficient operations.
Balance Sheet
85
Very Positive
The balance sheet of Bayer Cropscience India Limited is robust, with a low debt-to-equity ratio of 0.04 in 2025, indicating minimal leverage risk. The equity ratio is strong at 54.35%, showcasing a healthy capital structure. The company also maintains high levels of cash and equivalents, supporting liquidity and stability. Return on Equity (ROE) decreased slightly to 19.92% in 2025, yet remains impressive.
Cash Flow
70
Positive
Cash flow performance is mixed; operating cash flow decreased from 2024 to 2025, which could impact future investments. However, free cash flow generation is stable, and the free cash flow to net income ratio is robust, indicating good cash conversion. Despite the decline in operating cash flow, the company has maintained strong free cash flow growth in prior years.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue57.57B54.73B51.06B51.40B47.34B42.61B
Gross Profit21.57B20.59B21.81B23.09B20.57B17.99B
EBITDA6.81B6.43B9.43B8.86B7.90B7.80B
Net Income5.92B5.68B7.41B7.58B6.45B4.93B
Balance Sheet
Total Assets0.0052.46B45.97B46.79B43.53B42.39B
Cash, Cash Equivalents and Short-Term Investments9.21B9.29B12.11B9.02B8.19B12.57B
Total Debt0.001.05B471.00M735.00M864.00M263.00M
Total Liabilities-28.50B23.95B17.48B19.66B18.29B16.89B
Stockholders Equity28.50B28.50B28.49B27.12B25.24B25.50B
Cash Flow
Free Cash Flow0.002.59B9.06B5.32B1.60B6.45B
Operating Cash Flow0.003.00B9.52B6.09B2.15B6.87B
Investing Cash Flow0.00389.00M4.00M833.00M642.00M67.00M
Financing Cash Flow0.00-6.10B-6.56B-6.13B-7.03B-5.56B

Bayer Cropscience India Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4646.45
Price Trends
50DMA
4802.12
Negative
100DMA
5255.06
Negative
200DMA
5095.54
Negative
Market Momentum
MACD
-79.14
Negative
RSI
43.64
Neutral
STOCH
67.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAYERCROP, the sentiment is Negative. The current price of 4646.45 is above the 20-day moving average (MA) of 4588.41, below the 50-day MA of 4802.12, and below the 200-day MA of 5095.54, indicating a bearish trend. The MACD of -79.14 indicates Negative momentum. The RSI at 43.64 is Neutral, neither overbought nor oversold. The STOCH value of 67.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAYERCROP.

Bayer Cropscience India Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
₹558.73B34.670.47%-5.90%-14.80%
70
Outperform
₹638.98B26.570.50%32.88%75.74%
68
Neutral
₹639.95B29.080.79%8.14%
62
Neutral
₹192.74B11.012.27%19.70%22.23%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
₹232.50B42.850.26%8.69%12.26%
61
Neutral
₹217.34B36.682.74%8.92%5.06%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BAYERCROP
Bayer Cropscience India Limited
4,646.45
-1,094.69
-19.07%
IN:CHAMBLFERT
Chambal Fertilisers & Chemicals Ltd.
439.90
-74.18
-14.43%
IN:COROMANDEL
Coromandel International Limited
2,381.90
619.02
35.11%
IN:PIIND
PI Industries Limited
3,396.50
-682.33
-16.73%
IN:SUMICHEM
Sumitomo Chemical India Ltd.
465.80
-76.10
-14.04%
IN:UPL
UPL Limited
758.85
209.88
38.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 12, 2025